{"sections":[{"heading":"Computational drug repurposing and the O-1A standard","paragraphs":["Computational drug repurposing — also called drug repositioning or drug reprofiling — is a research discipline that applies computational methods to identify approved or investigational drugs that may be effective for diseases beyond their original indication. Researchers in this field develop and apply network pharmacology models, machine learning classifiers, chemical genomics approaches, and systems biology frameworks to integrate molecular target data, gene expression profiles, phenotypic screening results, and clinical outcomes data to predict and experimentally validate new therapeutic uses for known compounds. The field has attracted substantial research investment because computational approaches can reduce the time and cost of early-stage drug development by focusing experimental validation on candidates with established safety profiles.","The O-1A extraordinary ability standard requires evidence satisfying at least three of the eight regulatory criteria under 8 C.F.R. § 214.2(o)(3)(iii). Computational drug repurposing researchers typically anchor petitions on scholarly articles, NIH grant funding from NCATS, NCI, or NIGMS as evidence of peer recognition, and critical role within a research group or pharmaceutical informatics program, with original contributions to methods development and peer review service as supporting criteria. The field's intersection of computational biology, medicinal chemistry, pharmacology, and clinical data science means that relevant publications and funding span multiple NIH institute portfolios, and the petition should document funding across these sources to present a complete picture of research support.","The NIH National Center for Advancing Translational Sciences, founded in 2012 to catalyze the development and application of translational science methods, is the primary NIH institute for drug repurposing research. NCATS has funded drug repurposing research through the National COVID Cohort Collaborative, the Translational Science Award, the Cures Acceleration Network grant mechanism, and the Clinical and Translational Science Awards program. An NCATS-funded researcher operates within a federal program that was established specifically to address the pipeline bottlenecks in drug development — a framing that positions the petitioner's work as nationally significant by definition and that can be developed in the petition cover letter to explain why the petitioner's contributions are consequential beyond the research community."]},{"heading":"Research publications and impact in the field","paragraphs":["The scholarly articles criterion is supported by peer-reviewed publications in journals including Briefings in Bioinformatics, Bioinformatics, PLOS Computational Biology, Journal of Medicinal Chemistry, Drug Discovery Today, Nature Communications, and npj Systems Biology and Applications. First-author or corresponding-author publications that describe novel computational methods for drug-target interaction prediction, network-based drug repositioning, or machine learning approaches to therapeutic indication expansion are the most significant evidence items for this criterion. Publications should be presented with full citation information, impact factor, and citation count, supported by a Google Scholar printout showing the total publication record.","High-impact publications that describe successful computational predictions subsequently validated experimentally provide particularly strong evidence because they demonstrate that the petitioner's computational methods have real-world consequences for drug discovery. A paper published in Science Translational Medicine or Nature Medicine describing a computationally predicted drug repositioning candidate that showed efficacy in a clinical study or animal model has both scientific significance and translational impact that the petition can document through the number of citations and the downstream experimental work that cited the original computational prediction. Expert letters should explain the significance of such translational validations within the research community.","Contributions to public databases and software tools — repositories of drug-target interaction data, chemical similarity networks, or machine learning models distributed through GitHub, Zenodo, or Bioconductor — represent original contributions that may not be captured by traditional citation metrics but that have substantial influence on the field through downloads, usage by downstream researchers, and incorporation into standard computational pipelines. The petition should document these contributions with usage metrics from the repository, citations to the associated methods papers, and expert testimony characterizing the tool's adoption and influence within the computational drug discovery community."]},{"heading":"NIH and NSF grant funding as peer recognition","paragraphs":["NIH R01 funding from NCATS, NCI, NIA, NIGMS, or NIMH for computational drug repurposing research represents strong evidence of peer recognition through the competitive NIH review process. The petition should document each award with the title, award number, funding period, direct costs, and PI designation. For researchers who hold co-PI or key personnel positions on large-scale collaborative grants — U01, U54, or U19 consortium grants in precision medicine, cancer biology, or neurodegenerative disease — the petition should document the petitioner's specific intellectual contributions and leadership responsibilities within the collaboration rather than simply listing the grant.","NSF Division of Biological Infrastructure and Division of Mathematical Sciences grants support computational biology and bioinformatics research that intersects with drug discovery, and NSF funding provides evidence of peer recognition from a funding body with distinct review criteria from NIH. An NSF CAREER award — the agency's most prestigious award for early-career faculty — represents peer recognition that the petitioner demonstrates the potential for both outstanding research and excellent education, and the review process is distinct from NIH in involving both technical evaluation and an explicit assessment of the petitioner's teaching and outreach vision. Documentation of NSF CAREER funding alongside NIH research support demonstrates recognition from multiple independent peer review systems.","For computational drug repurposing researchers who have received funding from the NIH Common Fund programs — including the Undiagnosed Diseases Network, the Illuminating the Druggable Genome program, or the Genotype-Tissue Expression project — the petition should document these awards as evidence of recognition by trans-NIH program leadership who selected the petitioner's research as meriting support from the agency's highest-priority initiatives. The Common Fund supports research that individual NIH institutes cannot fund alone, and selection for Common Fund support reflects a determination that the petitioner's research addresses a gap at the frontier of biomedical science."]},{"heading":"Critical role and program leadership in drug repurposing","paragraphs":["The critical role criterion for computational drug repurposing researchers focuses on leadership within the research infrastructure — whether at an academic institution, a nonprofit research institute, or a pharmaceutical company research division. A researcher who directs a computational drug discovery core facility, leads the computational biology team within a large academic medical center's drug development program, or serves as the principal computational scientist for a multi-investigator research center occupies a role that is critical to the organization's research capability in that area. The petition should document the scope of the petitioner's role through organizational charts, letters from department chairs and program directors, descriptions of the infrastructure the petitioner maintains, and the list of research groups or clinical investigators who rely on the petitioner's computational resources.","For researchers at pharmaceutical and biotechnology companies, the critical role evidence is often strongest when it can document the petitioner's specific contributions to drug development programs that have advanced to clinical stages. A researcher who developed the computational approach that identified a drug repositioning candidate now in Phase 2 clinical trials has made a contribution whose significance is documented by the company's investment in clinical development. The petition should document this contribution through internal letters, patent filings, or published papers describing the candidate and its origins, and should explain that the petitioner's specific computational approach was essential to identifying the clinical-stage candidate.","Industry-based researchers face the challenge that some of the most significant evidence of their contributions may be confidential. The petition can address this by documenting publicly available evidence — patents with the petitioner as inventor, publications describing the methods without proprietary results, presentations at industry conferences, and press coverage of drugs the petitioner helped identify — while expert letters from academic collaborators or former colleagues who can speak to the petitioner's methods and their significance within the field provide the interpretive framing. A researcher whose computational methods have been licensed by multiple pharmaceutical companies, or who has published methods that industry researchers have adapted for internal use, has made an original contribution of commercial as well as scientific significance."]},{"heading":"Original contributions and peer review in computational drug discovery","paragraphs":["The original contributions criterion is satisfied by evidence of contributions that have changed the methods, tools, or conceptual frameworks used by researchers in the field. For computational drug repurposing researchers, the most significant original contributions typically fall into one of three categories: the development of novel machine learning or network-based methods that outperform prior approaches on benchmark tasks; the creation and public release of integrated databases that other researchers use as standard analytical resources; or the publication of large-scale analyses that establish new principles about the structure of drug-disease relationships, the transferability of drug mechanisms across disease contexts, or the genomic features that predict drug repurposing opportunities.","Peer review service for Briefings in Bioinformatics, Bioinformatics, PLOS Computational Biology, Journal of Cheminformatics, or Drug Discovery Today supports the judging criterion. For computational drug repurposing researchers, the judging criterion can also be supported by service as a reviewer or committee member for NIH study sections evaluating computational biology and drug development applications — the Macromolecular Structure and Function study section, the Biodata Management and Analysis study section, or the Clinical Molecular Imaging and Probe Development study section. NIH study section service implies that the peer review office and the Scientific Review Officer have identified the petitioner as qualified to evaluate research proposals in the field.","Conference participation at venues such as the American Chemical Society National Meeting and Exposition, the Pacific Symposium on Biocomputing, ISMB (Intelligent Systems for Molecular Biology), or the Drug Discovery Chemistry Conference provides evidence of expert recognition and peer community engagement. Invited talks at these conferences are extended to researchers whose work the organizing committees consider among the most significant in the relevant area. A researcher invited to present at a symposium on AI-assisted drug discovery at ISMB or to chair a session at the ACS drug repurposing symposium has been recognized by the organizing community as a researcher whose contributions merit prominent presentation to the international audience."]},{"heading":"Building a complete O-1A petition for computational drug repurposing","paragraphs":["A well-constructed O-1A petition for a computational drug repurposing researcher leads with the most concrete and objective evidence — peer-reviewed publications with citation data, NIH grant awards with funding amounts, and patent records with filing and grant dates — before presenting the more interpretive evidence of critical role and original contributions that requires expert framing to be fully persuasive. The cover letter should explain the field's significance to non-specialist adjudicators, situate the petitioner's work within the field's development, and guide the adjudicator through the evidence exhibit by exhibit with specific references to documents that support each criterion.","Expert letters for computational drug repurposing petitions should come from researchers who can speak to both the computational methods dimension and the drug discovery application dimension of the petitioner's work. A letter from a senior academic computational biologist who has cited the petitioner's methods in their own work provides methods-focused evidence of significance; a letter from a clinical pharmacologist or drug development scientist at a major academic medical center or research institution who has applied the petitioner's repositioning predictions in their experimental program provides applied significance evidence. Together, these letters frame the petitioner as recognized across the breadth of the field rather than in only one of its dimensions.","Timing the petition to coincide with a significant career milestone — the activation of an R01 award, the publication of a high-impact paper describing a successful repurposing prediction, or the transition to an independent faculty or senior scientist position — positions the application at a moment when the evidence of sustained recognition is most compelling. The AAO has upheld O-1A petitions for computational scientists whose records demonstrate a consistent pattern of recognition by funding agencies, journal peer review systems, and the broader research community, even when no single award or publication is individually iconic. A petition that presents this pattern comprehensively and coherently gives adjudicators the evidentiary basis to find that the totality of the evidence establishes sustained national and international acclaim."]}],"article":{"title":"O-1A for Computational Drug Repurposing Researchers: NIH and NSF Grants, Publications, and Field Recognition in 2026","excerpt":"Computational drug repurposing researchers face a complex O-1A evidentiary challenge that spans methods papers, NIH NCATS grant records, and cross-disciplinary peer recognition. This guide explains how to document scholarly articles, critical role, and original contributions for a petition in this rapidly growing field.","category":"O-1A Guide","date":"Sep 29, 2026","readTime":"8 min read"},"prev":{"title":"O-1A for Aquatic Photochemistry Researchers: NSF Chemical Oceanography Grants, Publications, and Field Recognition in 2026","slug":"o-1a-for-aquatic-photochemistry-researchers-nsf-chemical-oceanography-grants-publications-and-field-recognition-in-2026"},"next":{"title":"O-1A for Retinal Neurophysiology Researchers: NIH NEI Grants, ARVO Publications, and Field Recognition Evidence in 2026","slug":"o-1a-for-retinal-neurophysiology-researchers-nih-nei-grants-arvo-publications-and-field-recognition-evidence-in-2026"},"related":[{"title":"O-1A for Mushroom Cultivation Researchers: USDA SBIR Grants, Mycological Research Publications, and Field Recognition in 2026","slug":"o-1a-for-mushroom-cultivation-researchers-usda-sbir-grants-mycological-research-publications-and-field-recognition-in-2026"},{"title":"O-1A for Coral Genomics Researchers: NSF OCE Grants, Coral Reefs Journal Publications, and Field Recognition Evidence in 2026","slug":"o-1a-for-coral-genomics-researchers-nsf-oce-grants-coral-reefs-journal-publications-and-field-recognition-evidence-in-2026"},{"title":"O-1A for Aquatic Photochemistry Researchers: NSF Chemical Oceanography Grants, Publications, and Field Recognition in 2026","slug":"o-1a-for-aquatic-photochemistry-researchers-nsf-chemical-oceanography-grants-publications-and-field-recognition-in-2026"},{"title":"O-1A for Retinal Neurophysiology Researchers: NIH NEI Grants, ARVO Publications, and Field Recognition Evidence in 2026","slug":"o-1a-for-retinal-neurophysiology-researchers-nih-nei-grants-arvo-publications-and-field-recognition-evidence-in-2026"},{"title":"O-1A for Pangenomics Researchers: NIH Genome Research Grants, Genome Biology Publications, and Field Recognition in 2026","slug":"o-1a-for-pangenomics-researchers-nih-genome-research-grants-genome-biology-publications-and-field-recognition-in-2026"},{"title":"O-1A for Arctic Ecology Researchers: NSF Arctic Program Grants, Publications, and Field Recognition in 2026","slug":"o-1a-for-arctic-ecology-researchers-nsf-arctic-program-grants-publications-and-field-recognition-in-2026"}]}